Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Blood (2024) 144 (Supplement 1): 673.

https://doi.org/10.1182/blood-2024-209653

Published: 2024

Journal Articles

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Blood (2024) 144 (Supplement 1): 385.

https://doi.org/10.1182/blood-2024-209720

Published: 2024

Journal Articles

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Blood (2023) 142 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2023-188672

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Blood (2023) 142 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2023-187202

Published: 2023

Journal Articles

Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis

Blood (2021) 138 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2021-147043

Published: 2021

Journal Articles

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

Blood (2021) 138 (Supplement 1): 81.

https://doi.org/10.1182/blood-2021-146650

Published: 2021

Journal Articles

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study

Heinz Ludwig, MD, Evangelos Terpos, MD PhD, María-Victoria Mateos, MD PhD, Mario Boccadoro, Bhuvan Kishore, Karthik Ramasamy, Sylvie Fernandez, Fabio Ferri, Nawal Bent-Ennakhil, Athanasios Zomas, François Gavini, Roman Hajek, MD

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136519

Published: 2020

Journal Articles

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

Blood (2019) 134 (Supplement_1): 3153.

https://doi.org/10.1182/blood-2019-126207

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy, MD PhD, Spyros Kolovos, PhD, Guido Nador, MD, Rosemarie Finley, Matthew Streetly, MD, Bhuvan Kishore, Neil K Rabin, MD, Andrew D Chantry, PhD MD, Kwee Yong, MD PhD, John Ashcroft, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Mark T Drayson, Daniel Prieto-Alhambra, PhD MD, Cyrus Cooper, OBE, DL, FMedSci, Muhammad Kassim Javaid, MD PhD, Rafael Pinedo-Villanueva, PhD

Blood (2018) 132 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2018-99-114736

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 1854.

https://doi.org/10.1182/blood.V130.Suppl_1.1854.1854

Published: 2017

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

Journal Articles

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Shankaranarayana Paneesha, MD FRCP, FRCPath, Iman Qureshi, MBBS, MRCP, Malahat Saeed, MBBS MRCP, Richard Lovell, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath, Kathy Holder, Maria Kaparou

Blood (2016) 128 (22): 5868.

https://doi.org/10.1182/blood.V128.22.5868.5868

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

NARROW

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Single Centre Experience of Managing Patients with Double Hit Lymphoma

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only